Anticipatory Compounding - Mpje

1. What is the maximum anticipatory amount under USP <795> for a nonsterile prep with no stricter state law?

   A $30$-day supply. USP <795> sets a baseline 30-day limit for nonsterile anticipatory compounding to balance efficiency with regulatory compliance.

2. Find the correct limit: sterile IVs anticipatorily prepared for a clinic with consistent weekly orders.

   Only the quantity needed for expected demand supported by documented order history. USP <797> ties sterile anticipatory limits to evidence-based expectations to prevent excess and maintain sterility standards.

3. Identify if allowed: compounding a bulk batch to ship to multiple pharmacies without prescriptions.

   Not allowed (resembles manufacturing and non-patient-specific distribution). Bulk compounding for inter-pharmacy shipment without prescriptions mimics manufacturing, violating patient-specific compounding rules.

4. What is the USP definition of anticipatory compounding for sterile preparations?

   Compounding before receipt of a prescription based on a history of receiving orders. USP <797> permits sterile compounding ahead of time solely when justified by prior prescription records to maintain safety and relevance.

5. Identify if allowed: sterile syringes prepared anticipatorily with no documented order history.

   Not allowed (USP <797> requires documented order history). USP <797> mandates historical data for sterile preparations to justify quantities and ensure they meet genuine, recurring needs.

6. What is the maximum nonsterile anticipatory quantity if typical use is $2$ g/day and no stricter state law?

   $60$ g (a $30$-day supply at $2$ g/day). USP <795> bases nonsterile limits on typical usage patterns, calculating maximums from daily doses to avoid overcompounding.

7. What is the maximum anticipatory nonsterile amount if state law allows $30$ days but facility policy limits to $7$ days?

   A $7$-day supply (apply the most restrictive requirement). Facility policies can impose stricter limits than state or USP, requiring adherence to the most conservative rule for safety.

8. What must be true about BUD assignment for anticipatorily compounded preparations?

   BUD must be assigned per USP criteria and cannot be extended to justify larger anticipatory stock. USP requires proper BUDs based on stability data, independent of quantity limits, to ensure safety in anticipatory compounding.

9. What is the USP definition of anticipatory compounding for nonsterile preparations?

   Compounding before receipt of a prescription based on routine, regularly observed patterns. USP <795> allows nonsterile compounding in advance only when supported by established prescribing trends to ensure patient-specific needs.

10. What is the maximum nonsterile anticipatory quantity if typical use is $5$ mL/day and state limit is $10$ days?

    $50$ mL (a $10$-day supply at $5$ mL/day). State restrictions override USP when stricter, using daily usage to compute allowable anticipatory nonsterile quantities.

11. What is the correct action if anticipatorily compounded nonsterile stock exceeds the $30$-day limit?

    Reduce to compliant quantity; do not continue producing/holding excess anticipatory stock. USP <795> enforces quantity limits for nonsterile stock, requiring adjustments to comply and prevent regulatory violations.

12. Which record best supports anticipatory compounding quantities: invoices or prescription logs?

    Prescription/order logs (they demonstrate historical patient-specific demand patterns). Prescription logs provide evidence of patient-specific patterns, unlike invoices which track supplies but not demand history.

13. Identify if allowed: nonsterile capsules compounded anticipatorily for a prescriber who occasionally orders them.

    Not allowed unless demand is routine and regularly observed (documented pattern required). USP <795> requires consistent demand patterns for nonsterile anticipatory compounding to ensure it's not speculative production.

14. What is the USP <797> limit on anticipatory compounding for sterile preparations?

    Only quantities necessary to meet expected needs based on documented order history. USP <797> ensures sterile anticipatory compounding remains limited to verifiable past demands to avoid manufacturing-like activities.

15. Which documentation is required to justify anticipatory compounding under USP standards?

    Documented history of prior prescriptions/orders showing routine, regularly observed demand. USP standards mandate evidence of consistent demand to validate anticipatory compounding and distinguish it from unauthorized manufacturing.

16. What must a pharmacy do if state law is more restrictive than USP on anticipatory compounding?

    Follow the more restrictive requirement (state law prevails if stricter). Pharmacies must comply with the strictest applicable rule to uphold safety and legal standards in compounding practices.

17. What is the common MPJE rule for dispensing compounded stock made anticipatorily?

    Dispense only pursuant to a valid prescription/order; do not sell as general inventory. MPJE guidelines require patient-specific orders for compounded items to prevent unauthorized distribution and ensure proper use.

18. Identify whether this is compliant: labeling anticipatorily compounded stock with no lot/batch identifier.

    Not compliant (batch/lot identification is required for traceability and recall management). USP standards mandate batch identifiers on compounded preparations for effective tracking and quality control in case of issues.

19. What is the USP <795> limit on anticipatory compounding for nonsterile preparations?

    No more than a $30$-day supply (or state limit, whichever is less). USP <795> restricts nonsterile anticipatory amounts to prevent overproduction, aligning with state regulations if they impose tighter controls.

20. Identify the factor that most strongly indicates impermissible manufacturing activity.

    Producing large batches for general distribution without patient-specific demand history. Large-scale production without tied prescriptions violates compounding exemptions and crosses into regulated manufacturing under federal law.

21. What is the maximum anticipatory amount allowed if state law limits nonsterile to $14$ days?

    A $14$-day supply. State laws take precedence when stricter than USP, limiting quantities to maintain control over compounding activities.

22. What is the best practice to set anticipatory quantities for a sterile product used in a hospital unit?

    Use documented order history (e.g., average use) and prepare only what is needed for expected demand. Best practices under USP <797> use historical data to forecast sterile needs accurately, minimizing waste and ensuring compliance.

23. Identify whether this is allowed: nonsterile cream compounded anticipatorily as a $45$-day supply.

    Not allowed under USP <795> ($>30$-day supply). Exceeding the 30-day USP <795> threshold for nonsterile preparations violates limits designed to tie production to anticipated needs.

Study these flashcards